What exactly did Jefferies change for DGX on February 10, 2026?

Jefferies maintained its **Buy** rating on DGX and raised the price target to **$220** from **$215** on February 10, 2026. The action kept the positive view while slightly lifting the valuation benchmark.

How should investors interpret a maintained Buy with a higher price target?

A maintained Buy with a higher target signals continued analyst confidence and modest upside on valuation. It means the analyst expects outperformance versus the market but not a major shift in underlying business view.

Does the Meyka AI grade affect the DGX analyst rating?

Meyka AI’s **B+** grade is an independent composite based on benchmarks, sector performance, growth, and analyst consensus. It complements but does not change the Jefferies **DGX analyst rating**.

Where can I read the analyst note and recent earnings coverage?

Jefferies’ price-target update appeared on The Fly on February 10, 2026 [source](https://thefly.com/permalinks/entry.php/id4289577/2762286394/DGX-Quest-Diagnostics-price-target-raised-by--at-Jefferies-heres-why). Recent Q4 earnings coverage and the outlook summary are available via Seeking Alpha [se

Analyst Ratings

Jefferies Maintains Buy on Quest Diagnostics (DGX) Feb 10, 2026

ByDanny Kontos February 11, 2026February 11, 2026

Jefferies maintained a Buy on Quest Diagnostics Incorporated (DGX) on February 10, 2026. This update affects the DGX analyst rating and raises the price target to $220 from $215. The firm left the underlying Buy view intact while nudging the valuation higher after recent company results. Meyka AI, an AI-powered market analysis platform, flags the move as confirmation of improving operational momentum and favorable 2026 guidance.